Nextcure provides business update and reports first quarter 2024 financial results

Beltsville, md., may 02, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.

NXTC Ratings Summary

NXTC Quant Ranking